GlassScriptPhysician profile
Heidi M Schmidt
NPI 1194034942
$1,517.35
in general payments reported to CMS, 2019-2025
21 companies · $315 in 2025
The $315 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $95.33 · 2022: $303 · 2023: $422 · 2024: $382 · 2025: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,119.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $228.91 | 2021-2024 | Orladeyo |
| Kaleo, INC. | $153.73 | 2021-2024 | Auvi-Q |
| Csl Behring | $138.26 | 2022-2025 | Andembry, Hizentra, Haegarda |
| Takeda Pharmaceuticals U.S.A., INC. | $111.20 | 2022-2025 | Cuvitru |
| Horizon Therapeutics Plc | $108.83 | 2022 | |
| Pharming Healthcare, INC. | $88.22 | 2023 | Joenja |
| Glaxosmithkline, LLC. | $79.71 | 2021-2025 | Nucala, Shingrix, Trelegy Ellipta |
| Dermavant Sciences, INC. | $75.00 | 2024 | Vtama |
| Incyte Corporation | $69.43 | 2022-2025 | Opzelura |
| Genzyme Corporation | $60.47 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $59.36 | 2024-2025 | Dupixent |
| Phadia US INC. | $49.62 | 2022-2023 | Immunocap |
| Galderma Laboratories, L.P. | $39.51 | 2025 | Nemluvio |
| Pfizer INC. | $36.37 | 2022-2023 | |
| Aimmune Therapeutics, INC. | $34.80 | 2021-2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gc Biopharma USA, INC. | $33.80 | 2025 | Alyglo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.77 | 2022 | |
| Genentech USA, INC. | $32.06 | 2023 | Xolair |
| Astrazeneca Pharmaceuticals LP | $31.55 | 2025 | |
| Greer Laboratories, INC. | $30.03 | 2025 | Palforzia |
| Alk-Abello, INC | $23.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.